此番交易恰逢礼来股价异动引发华尔街关注之际。Haggerston BioHealth投资组合经理埃德蒙·英格汉姆称此次回调是"长期投资者难得的买入机会"，但Crude Value Insights投资组合经理丹尼尔·琼斯则认为该股票对同类型投资者群体的上行空间有限。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.